Concepedia

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

David A. Sallman, Tessa Kerre, Violaine Havelange, Xavier Poiré, Philippe Lewalle, Eunice S. Wang, Jason Brayer, Marco L. Davila, Ine Moors, Jean‐Pascal Machiels,

The Lancet Haematology · 2023 · 93 citations · 18 references

Open access

References

18

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text

Life Sciences, Hematology, Immunology +17

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson · Blood · 2006 · 1.6K citations

Medicine, Hematology, Hematopathology +9

Design and Analysis of Phase I Clinical Trials

Barry E. Storer · Biometrics · 1989 · 932 citations

Public Health, Biostatistics, Pharmacology +9

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

James N. Kochenderfer, Robert Somerville, Tangying Lu et al. · Journal of Clinical Oncology · 2017 · 561 citations

Medicine, Hematology, Immunology +17

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Saar Gill, Sarah K. Tasian, Marco Ruella et al. · Blood · 2014 · 491 citations · Full text

Life Sciences, Immunology, Oncology +17